Aarti Drugs Subsidiary Receives 3 Observations from US FDA

Aarti Drugs Ltd announced that its subsidiary, Pinnacle Life Science Private Limited, underwent an inspection by the US FDA at its Baddi facility from November 2nd to 6th, 2026. The inspection resulted in 3 observations in Form 483, none of which were related to data integrity. The company stated there would be no impact on financial, operational, or other activities. Pinnacle Life Science will work with the US FDA to resolve the noted points.